BIOSTAT-CHF

Facilitate personalized therapies in patients with heart failure

1 Current vacancy for BIOSTAT-CHF

Bachelor and Master students

Project: BIOSTAT-CHF, Early Synergy, GIPS-IV trial, Adiposity in Heart Failure with Preserved Ejection Fraction, iPHORECAST, KETONE-HF, RACE‐8‐HF, RED-CVD, SECRETE-HF, Selenium and Heart Failure, STOP-HF, PLN cardiomyopathy, AF RISK, APAF-CRT, RACE 9, RASTA AF Research line: Heart Failure, Ischemic Heart Diseases, Experimental Cardiology, Atrial Fibrillation

More about this vacancy

BIOSTAT-CHF

BIOSTAT-CHF is a EU-funded large scale project with the main aim to facilitate personalized therapies in patients with heart failure. BIOSTAT-CHF stands for: A systems BIOlogy Study to Tailored Treatment in Chronic Heart Failure.

We use several artificial intelligence applications (such as network/pathway analyses, cluster analyses, machine learning en system biology) using large scale -omics data (genomics, proteomics, transcriptomics, and biomarkers) to get a better insight in the pathophysiology of specific groups of patients with heart failure, leading to better and more personalized therapies of patients with heart failure.
From 2010-2015 data from 2 large cohorts of patients with heart failure ( n=2516 and n=1738) were collected and information on clinical outcome was captured. During a median of 21 months, 45% of patients died or had to be hospitalized for worsening of heart failure, indicating the severity of this disease.

From 2015 – now, a large group of researchers have performed various analyses and in the meantime more than 50 papers are published from this project, all of which were published in Q1 journals.

We are currently looking for PhD students and post-docs, both medical doctors, (medical) biologists and statisticians and bio-informaticians to support future studies to learn more about pathways related to disease progression, with specific attention to sex-differences, atrial fibrillation, diabetes and the differences between patients with heart failure with preserved and reduced ejection fraction (HFpEF versus HFrEF)

“A large group of researchers have performed various analyses and in the meantime more than 50 papers are published from this project”

People involved

Principal investigator

Adriaan Voors

Cardiologist
Team

Rudolf de Boer

Cardiologist

Peter van der Meer

Cardiologist

Dirk Jan van Veldhuisen

Cardiologist

Lisa Emmens

Physician-scientist

Sylwia Figarska

Bioinformatician

Jozine ter Maaten

Physician-scientist

Iziah Sama

Bioinformatician

Karla Fernanda Arevalo Gomez

PhD Student

George Markousis-Mavrogenis

MD/PhD Student

Bernadet Santema

Physician-scientist

International collaborations

  • Prof. Stefan D. Anker, Berlin , Germany
  • Prof John G. Cleland. Glasgow, UK
  • Prof. Kenneth Dickstein, Stavanger, Norway
  • Prof. Gerasimos Filippatos, Athens, Greece
  • Prof. Chim C. Lang, Dundee, UK
  • Prof. Leong Ng, Leicester, UK
  • Prof. Piotr Ponikowski, Wroclaw, Poland
  • Prof. Nilesh J. Samani. Leicester, UK
  • Prof. Faiez Zannad, Nancy, France
  • Prof. Marco Metra, Brescia, Italy
  • Prof. Carolyn Lam. Singapore

Press & publications

Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study.

Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V, Hillege H, Samani NJ, Zannad F, Dickstein K, Lang CC, Cleland JG, Ter Maaten JM, Metra M, Anker SD, van der Harst P, Ng LL, van der Meer P, van Veldhuisen DJ, Meyer S, Lam CSP, ASIAN-HF investigators, Voors AA. Lancet 2019

view on publisher site

Novel endotypes in heart failure: effects on guideline-directed medical therapy.

Tromp J, Ouwerkerk W, Demissei BG, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, van der Meer P. Eur Heart J. 2018

view on publisher site

Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction.

Tromp J, Westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Lang CC, Ng LL, Zannad F, Zwinderman AH, Hillege HL, van der Meer P, Voors AA. J Am Coll Cardiol. 2018

view on publisher site

Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction.

Santema BT, Kloosterman M, Van Gelder IC, Mordi I, Lang CC, Lam CSP, Anker SD, Cleland JG, Dickstein K, Filippatos G, Van der Harst P, Hillege HL, Ter Maaten JM, Metra M, Ng LL, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, Van der Meer P, Rienstra M, Voors AA. Eur Heart J 2018

view on publisher site

Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.

Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Ter Maaten JM, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Metra M, Zwinderman AH. Eur Heart J. 2017

view on publisher site

Press: Heart failure patients consuming more protein live longer

Heart failure patients who have a higher protein intake live longer, according to new research presented at Heart Failure 2018 and the World Congress on Acute Heart Failure, a European Society of Cardiology (ESC) congress.

Read the article

Press: Heart failure patients with a higher protein intake live longer

Heart failure patients who consume more protein live longer, according to research presented today at Heart Failure 2018 and the World Congress on Acute Heart Failure, a European Society of Cardiology congress.

Read the article

Press: High-protein diet can help heart patients to survive

Patients with heart failure who eat more protein live longer, according to a study.

Read the article

Press: Vrouwen kunnen na hartfalen toe met lagere dosis medicijnen (only in Dutch)

De optimale dosering van medicatie voor vrouwen met hartfalen ligt aanzienlijk lager dan voor mannen. Dat blijkt uit een internationaal onderzoek onder leiding van het Universitair Medisch Centrum Groningen dat is verschenen in het wetenschappelijke toptijdschrift The Lancet.

Read the article